Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow PHAR
Pharming Group N.V. Sponsored ADR (PHAR) P/E ratio
As of 16 October 2026, Pharming Group N.V. Sponsored ADR (PHAR) trades at a P/E ratio of 62.4×. Over the past ten years it has ranged from 0.0× (September 2025) to 1,809× (December 2025); the current reading is higher than 56% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 442× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 60.7× | (3.59%) |
| FY2021 | 63.0× | (18.51%) |
| FY2020 | 77.3× | (4.26%) |
| FY2019 | 80.8× | 0.00% |
| FY2018 | 80.8× | 0.00% |
| FY2017 | 80.8× | 0.00% |
| FY2016 | 80.8× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 92.6× | 5.73% |
| Mar 2026 | 87.6× | (80.17%) |
| Dec 2025 | 442× | (69.53%) |
| Sep 2025 | 1,450× | — |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CADL Candel Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| OABI OmniAb, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR | 62.4× |
| MDXG MiMedx Group, Inc compare | 111× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)